PARIS (Reuters) -Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, ...

Healthcare & Pharmaceuticalscategory US CDC advisers begin review of vaccine guidelines after months-long delay 3:43 PM UTC · Updated ago Healthcare & Pharmaceuticalscategory Bristol Myers' heart ...

The pharmaceutical giant scrapped development of a once-daily GLP-1 pill after a person involved in the drug’s trial suffered a liver injury.

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia Cavazzoni, M.D., stepped down in January and joined Pfizer's C-suite as chief ...

In an interview, the US pharmaceuticals giant’s international chief says Australia has made no progress in making life easier for medicine developers.

The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

So far this year, Pfizer shares have dropped 17.4%, while Novo Nordisk's stock has tumbled 24% and Lilly shares have slipped 3.2%. The SPDR S&P Pharmaceuticals ETF XPH has shed 12.1% year to date and ...

Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

Pfizer (PFE) stock was up on Monday despite the pharmaceutical company ending the clinical trial of its once-daily GLP-1 weight loss pill, danuglipron. The company had to cut this trial off early ...